A5052849720- Chronic Kidney Disease and Diabetes
- Renal Diseases and Glomerulopathies
- Dialysis and Renal Disease Management
- Parathyroid Disorders and Treatments
- Blood Pressure and Hypertension Studies
- Renal and Vascular Pathologies
- Bone health and treatments
- Bone health and osteoporosis research
- Protein Kinase Regulation and GTPase Signaling
- Organ Donation and Transplantation
- Vasculitis and related conditions
- PI3K/AKT/mTOR signaling in cancer
- Vitamin D Research Studies
- Cell Adhesion Molecules Research
- Medical Imaging and Pathology Studies
- Renal Transplantation Outcomes and Treatments
- Pharmacological Effects and Toxicity Studies
- Bone and Joint Diseases
- Renal and related cancers
- Transplantation: Methods and Outcomes
- Diabetes Treatment and Management
- Acute Kidney Injury Research
- Biomedical Research and Pathophysiology
- Liver Disease Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
Sheffield Kidney Institute
2014-2024
Sheffield Teaching Hospitals NHS Foundation Trust
2016-2024
The Royal Free Hospital
2024
Roland Hill (United Kingdom)
2024
University College London
2024
Cardiff University
2024
University of Sheffield
2022
Northern General Hospital
2009-2020
National Health Service
2018
King's College London
2000-2006
tion’, implying that most patients ‘should’ receive a particular action. In contrast, level 2 guidelines are essentially ‘suggestions’ and deemed to be ‘weak’ or discretionary, recognising management decisions may vary in different clinical contexts. Each recommendation was further graded from A D by the quality of evidence underpinning them, with grade referring high whilst recognised ‘very low’ base. The overall strength supporting is summarised table 1 . focused on 4 key domains: (1) AKI...
Renin-angiotensin system (RAS) inhibitors - including angiotensin-converting-enzyme (ACE) and angiotensin-receptor blockers (ARBs) slow the progression of mild or moderate chronic kidney disease. However, results some studies have suggested that discontinuation RAS in patients with advanced disease may increase estimated glomerular filtration rate (eGFR) its decline.In this multicenter, open-label trial, we randomly assigned progressive (eGFR, <30 ml per minute 1.73 m2 body-surface area)...
Blood pressure (BP) control and reduction of urinary protein excretion using agents that block the renin–angiotensin aldosterone system are mainstay therapy for chronic kidney disease (CKD). Research has confirmed benefits in mild CKD, but data on angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use advanced CKD lacking. In STOP-ACEi trial, we aim to confirm preliminary findings which suggest withdrawal ACEi/ARB treatment can stabilize even improve renal...
Background Renal osteodystrophy is common in advanced CKD, but characterization of bone turnover status can only be achieved by histomorphometric analysis biopsy specimens (gold standard test). We tested whether biomarkers and high-resolution peripheral computed tomography (HR-pQCT) parameters predict determined histomorphometry. Methods obtained fasting blood samples from 69 patients with CKD stages 4–5, including on dialysis, 68 controls for biomarker (intact parathyroid hormone [iPTH],...
In September 2017, KDIGO (Kidney Disease: Improving Global Outcomes) convened a Controversies Conference titled Blood Pressure in Chronic Kidney Disease (CKD). The purpose of the meeting was to consider which recommendations from 2012 Clinical Practice Guideline for Management CKD should be reevaluated based on new evidence clinical trials. Participants included multidisciplinary panel and scientific experts. Discussions focused optimal means measuring blood pressure (BP) as well managing BP...
Limited survival data are available on chronic kidney disease stage 5 (CKD 5) patients who opt for conservative management rather than dialysis.To measure in such and investigate potential factors predicting survival.Retrospective analysis of a cohort conservatively managed CKD from single center.Survival was measured 69 the time they were first known to have 5. Comorbidities, residual renal function other laboratory parameters (calcium, phosphate, parathyroid hormone, albumin hemoglobin)...
Timothy Ellam and colleagues argue for a focus on what diagnosis means individual patients rather than population risks Around half of people aged over 75 meet current diagnostic criteria chronic kidney disease (CKD). However, labelling them all as diseased is controversial may cause unnecessary anxiety.1 2 The classification system defining this epidemic CKD in elderly validated primarily an epidemiological risk stratification tool clinical aid to patient management. We highlight the need...
ABSTRACT. Targeting the Ras family of monomeric GTPases has been suggested as a therapeutic strategy in proliferative renal diseases. This article reports effects antagonist farnesylthiosalicylic acid (FTS) rat thy-1 nephritis, model which cytokine-driven glomerular cell proliferation and invasion is likely to involve signaling pathways. FTS vitro specifically inhibits binding discrete membrane sites, thereby downregulating several Ras-dependent functions accelerating degradation. Forty-four...
Chylous ascites is a rare complication in patients undergoing peritoneal dialysis. It may occur due to traumatic dialysis catheter insertion or other causes. important be aware of this condition as it confused with peritonitis, and antibiotics inappropriately administered. We report case chylous occurring after discuss management condition.
Renin-angiotensin system (RAS) inhibitors are considered first-line agents for hypertensive patients with progressive chronic kidney disease (CKD). In a previous study, we showed that stopping RAS increased estimated glomerular filtration rate (eGFR) in significant number of advanced CKD patients. The present study tries to address who would benefit and whether this is predictable.Forty-three stage 4 had stopped were followed at least 24 months. Compared outcome groups 'alive', 'renal...